Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4576 Target Snapshot

Homeodomain-interacting protein kinase 2 · SINGLE PROTEIN · Homo sapiens

1,423Compounds
311Assays
11Approved Drugs
886.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9H2X6. Use UniProt Q9H2X6 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9H2X6 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Homeodomain-interacting protein kinase 2 as ChEMBL target CHEMBL4576, mapped to UniProt Q9H2X6. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Homeodomain-interacting protein kinase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4576
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9H2X6
Homeodomain-interacting protein kinase 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Homeodomain-interacting protein kinase 2 is the right protein anchor across sources, using UniProt Q9H2X6 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHomeodomain-interacting protein kinase 2
UniProt AccessionQ9H2X6
Component TypeProtein
Sequence Length1198 aa

Homeodomain-interacting protein kinase 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Homeodomain-interacting protein kinase 2, mapped to UniProt Q9H2X6. Sequence length is 1198 aa.

Mapped IDQ9H2X6
Review nameHomeodomain-interacting protein kinase 2
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

11
Approved
7
Phase III
10
Phase II
7
Phase I
Assay Mix

Activity Type Distribution

IC50105.0
KI696.0
KD85.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1997554 8.4 Ki 3.981 Preclinical
CHEMBL4750420 8.3 IC50 5.0 Preclinical
CHEMBL1987448 8.2 Ki 6.31 Preclinical
CHEMBL1983932 8.2 Ki 6.31 Preclinical
CHEMBL243298 8.2 Ki 6.31 Preclinical
CHEMBL243518 8.2 Ki 6.31 Preclinical
CHEMBL385478 8.2 Ki 6.31 Preclinical
CHEMBL574738 8.14 Kd 7.3 Preclinical
CHEMBL1999931 8.1 Ki 7.943 Preclinical
CHEMBL1967662 8.1 Ki 7.943 Preclinical
Distribution

pChEMBL Value Distribution

8
5.0
83
5.5
90
6.0
92
6.5
71
7.0
40
7.5
11
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
ABEMACICLIB
CHEMBL3301610
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
RUXOLITINIB
CHEMBL1789941
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
Assay Landscape

Assay Landscape

311
Total Assays
278
Tested Compounds
2
Assay Types
Binding — 310 assays, 100 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 258 96 6.5
assay format 37 1 5.9
cell-based format 15 3 6.4
Functional — 1 assays, 278 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 278 6.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine